TRCT
ORIC icon

Tower Research Capital (TRC)’s Oric Pharmaceuticals ORIC Stock Holding History

Tower Research Capital (TRC)’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.6K Sell
2,920
-6,064
-67% -$55K ﹤0.01% 3135
2026
Q1 		$114K Buy
8,984
+8,541
+1,928% +$97K ﹤0.01% 2084
2025
Q4 		$3.62K Sell
443
-2,915
-87% -$33.6K ﹤0.01% 4338
2025
Q3 		$40.3K Sell
3,358
-8,399
-71% -$88.4K ﹤0.01% 2708
2025
Q2 		$119K Buy
11,757
+10,913
+1,293% +$73.3K ﹤0.01% 2238
2025
Q1 		$4.71K Sell
844
-13,817
-94% -$121K ﹤0.01% 4209
2024
Q4 		$118K Buy
14,661
+13,384
+1,048% +$123K ﹤0.01% 2065
2024
Q3 		$13.1K Sell
1,277
-3,726
-74% -$36.8K ﹤0.01% 3542
2024
Q2 		$35.4K Buy
5,003
+4,253
+567% +$38.1K ﹤0.01% 3362
2024
Q1 		$10.3K Sell
750
-8,505
-92% -$101K ﹤0.01% 3713
2023
Q4 		$85.1K Buy
9,255
+1,517
+20% +$11K ﹤0.01% 2761
2023
Q3 		$46.8K Buy
7,738
+5,635
+268% +$46.2K ﹤0.01% 2600
2023
Q2 		$16.3K Buy
+2,103
New +$11.9K ﹤0.01% 3570
2023
Q1 		– Sell
-9,077
Closed -$53K – 6157
2022
Q4 		$53K Buy
9,077
+2,110
+30% +$7.12K ﹤0.01% 2304
2022
Q3 		$22K Sell
6,967
-5,126
-42% -$20.5K ﹤0.01% 3868
2022
Q2 		$55K Sell
12,093
-5,437
-31% -$21.7K ﹤0.01% 2799
2022
Q1 		$94K Buy
17,530
+16,717
+2,056% +$151K ﹤0.01% 2250
2021
Q4 		$12K Sell
813
-1,697
-68% -$26.5K ﹤0.01% 4308
2021
Q3 		$53K Buy
2,510
+647
+35% +$13.1K ﹤0.01% 2921
2021
Q2 		$32K Buy
1,863
+311
+20% +$6.82K ﹤0.01% 3428
2021
Q1 		$38K Sell
1,552
-1,083
-41% -$34.2K ﹤0.01% 3356
2020
Q4 		$89K Sell
2,635
-5,093
-66% -$146K ﹤0.01% 2461
2020
Q3 		$193K Buy
7,728
+7,290
+1,664% +$174K ﹤0.01% 2610
2020
Q2 		$15K Buy
+438
New +$14K ﹤0.01% 3820

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s ORIC Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Oric Pharmaceuticals (ORIC) stake by 67% in Q2 2026, selling an estimated $55K and leaving 2,920 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3135.

Tower Research Capital (TRC) first reported a position in ORIC in Q2 2020 and has held it in 24 quarters since. The position peaked at $193K in Q3 2020. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Tower Research Capital (TRC) held 2,920 shares of Oric Pharmaceuticals worth $31.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 6,064 Oric Pharmaceuticals shares in Q2 2026, an estimated $55K.
  • Oric Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3135 holding.
  • Tower Research Capital (TRC) first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Oric Pharmaceuticals position peaked at $193K in Q3 2020.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.